Combination of Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Trial Profile

Combination of Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Preliminary results (n=63) assessing potential activity of immune checkpoint antibodies in patients with previously treated or untreated myelodysplastic syndromes, presented at the 22nd Congress of the European Haematology Association.
    • 17 May 2017 Status changed from active, no longer recruiting to recruiting.
    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top